AstraZeneca (AZN) has released positive results associated with Enhertu (trastuzumab deruxtecan), the first-of-its-kind HER2 directed antibody-drug conjugate (ADC). It is jointly developed by Daiichi Sankyo Company Limited (DSKYF) and AstraZeneca. The antibody-drug is developed to treat adult patients with unresectable or metastatic HER2-positive breast cancer.  Daiichi Sankyo is engaged in the research, development, manufacture, and sale of pharmaceuticals, while AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company.  Results showed significant progression-free survival (PFS) and overall survival (OS) in patients with “HR-positive or HR-negative HER2-low unresectable or metastatic breast cancer” versus chemotherapy.  Interestingly, Enhertu extended survival over six months in patients suffering from advanced breast cancer.
https://www.tipranks.com/news/astrazeneca-breast-cancer-drug-shows-positive-results?utm_source=advfn.com&utm_medium=referral